Jing Yang

Jing Yang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2024 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
QLQing Liu
Qing Liu
ZLZiyu Liu
Ziyu Liu
WXWenmeng Xie
Wenmeng Xie
YLYibo Li
Yibo Li
HWHongfang Wang
Hongfang Wang
LWLei Wang
Lei Wang
Background: N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin widely used to induce PD models, but the effect of MPTP on the cells and genes of PD has not been fully elucidated.Methods: Single-nucleus RNA sequencing was performed in the Substantia Nigra (SN) of MPTP mice. UMAP analysis was used for the dimensionality reduction visualization of the SN in the MPTP mice. Known marker genes highly expressed genes in each cluster were used to annotate most clusters. Specific Differentially Expressed Genes (DEGs) and PD risk genes analysis were used to find MPTP-associated cells. GO, KEGG, PPI network, GSEA and CellChat analysis were used to reveal cell type-specific functional alterations and disruption of cell-cell communication networks. Subset reconstruction and pseudotime analysis were used to reveal the activation status of the cells, and to find the transcription factors with trajectory characterized.Results: Initially, we observed specific DEGs and PD risk genes enrichment in microglia. Next, We obtained the functional phenotype changes in microglia and found that IGF, AGRN and PTN pathways were reduced in MPTP mice. Finally, we analyzed the activation state of microglia and revealed a pro-inflammatory trajectory characterized by transcription factors Nfe2l2 and Runx1.Conclusion: Our work revealed alterations in microglia function, signaling pathways and key genes in the SN of MPTP mice.

13 October 2023 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
HGHui Guo
Hui Guo
YZYilin Zhao
Yilin Zhao
RMRui Mu
Rui Mu
GZGuangdao Zhang
Guangdao Zhang
SCShuxian Chen
Shuxian Chen
JYJing Yang
Jing Yang

1 February 2026 in Acta Biochimica et Biophysica Sinica
Verified
Journal Article
Open access
PDF file
JHJiabing Han
Jiabing Han
XLXuyan Li
Xuyan Li
YDYiming Dong
Yiming Dong
YWYidan Wang
Yidan Wang
SLSimeng Lv
Simeng Lv
CWChuan Wang
Chuan Wang
The clinical use of doxorubicin (DOX) as a chemotherapeutic agent is limited by its cardiotoxic effects. Fibroblast growth factor (FGF) isoform 13, a distinct type of FGF, has been increasingly recognized as an important regulator of cardiovascular disease. However, its role in doxorubicin-induced cardiotoxicity remains unknown. Therefore, the objective of this study is to investigate the role and mechanism of FGF13 in doxorubicin-induced cardiac injury. C57BL/6 mice are used to establish Dox-induced cardiotoxicity models. The results reveal that mouse weight, cardiomyocyte cross-sectional area, ejection fraction and fractional shortening are decreased in the DOX group. In contrast, Fgf13 deficiency mitigate doxorubicin-mediated cardiotoxicity, as indicated by increased mouse weight, cardiomyocyte cross-sectional area, ejection fraction and fractional shortening. Mechanistically, the protein expressions of bax and cleaved caspase 3 are elevated in the DOX-treated group, along with decreased JC-1 fluorescence intensity and bcl-2 expression, whereas Fgf13 knockout prevented these alterations. In addition, Parkin, but not p53, interact with FGF13 and is upregulated in response to Fgf13 deficiency in a mouse model of doxorubicin-induced cardiotoxicity. Overall, Fgf13 knockout attenuates doxorubicin-induced cardiomyocyte apoptosis and mitochondrial damage through the modulation of Parkin, indicating that FGF13 may serve as a promising therapeutic target for DOX-induced cardiotoxicity.

31 August 2022 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
JYJiajia Yuan
Jiajia Yuan
JSJunzhe Song
Junzhe Song
CCChao Chen
Chao Chen
XLXue Lv
Xue Lv
JBJie Bai
Jie Bai
YZYuan Zhou
Yuan Zhou

Verified
Journal Article
Open access
PDF file
JYJing Yang
Jing Yang
YLYuanheng Li
Yuanheng Li
YFYixuan Feng
Yixuan Feng
YCYixuan Chen
Yixuan Chen
ZLZhongyuan Li
Zhongyuan Li
WZWenchong Zou
Wenchong Zou
The liver constitutes a vital organ characterized by remarkable regenerative capacity, wherein intra-hepatic cellular senescence and regeneration exert pivotal regulatory functions in maintaining hepatic homeostasis and in developing therapeutic interventions for liver diseases. Intra-hepatic cellular aging is typically characterized by diminished proliferative capacity, genomic instability, mitochondrial dysfunction, and exacerbated inflammatory responses, all of which contribute to hepatic functional impairment and the pathogenesis of associated diseases. Liver regeneration depends upon the proliferation and differentiation of hepatocytes—processes stringently regulated by diverse signaling pathways and microenvironmental factors. Notably, the relationship between hepatocyte aging and regeneration embodies a fundamental paradox: whereas acute, transient senescence may facilitate tissue repair through the senescence-associated secretory phenotype (SASP), chronic accumulation of senescent cells disrupts the hepatic microenvironment and suppresses regenerative capacity. This duality necessitates nuanced therapeutic strategies capable of distinguishing between beneficial and detrimental senescent cell populations. Interventions targeting cellular senescence, encompassing small-molecule anti-aging compounds, gene therapy, and stem-cell-based approaches, may represent promising therapeutic modalities for future liver disease management. This review reviews the molecular mechanisms underlying hepatocyte aging and regeneration, critically examines the contradictory roles of senescence in hepatic repair, and explores strategies that selectively target pathological senescence to promote liver regeneration. These insights may provide novel perspectives for the prevention and treatment of liver diseases.